

DRUGS FOR TREATING MENTAL DISORDERS: TECHNOLOGIES AND GLOBAL MARKETS



PHM074B
February 2014

Shalini Shahani Dewan
Project Analyst

ISBN: 1-56965-685-1

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	3
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ABOUT THE AUTHOR	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH ONLINE SERVICES	4
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL REVENUE OF DRUGS USED IN MENTAL DISORDERS, THROUGH 2018 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL REVENUE OF DRUGS USED IN MENTAL DISORDERS, 2011-2018 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
DEFINITIONS	10
CAUSES OF MENTAL DISORDERS	10
BIOLOGICAL FACTORS	10
Genetics (Heredity)	11
Infections	11
Prenatal Damage	11
Substance Abuse	11
Other Factors	11
PSYCHOLOGICAL FACTORS	11
ENVIRONMENTAL FACTORS	12
TYPES OF MENTAL DISORDERS	12
DEPRESSION	12
Signs and Symptoms	12
Causes and Risk Factors	13
Forms of Depression	13
ANXIETY DISORDERS	14
Signs and Symptoms	14
Causes and Risk Factors	15
Forms of Anxiety Disorders	15
SCHIZOPHRENIA	17
Signs and Symptoms	17
Causes and Risk Factors	17
Forms of Schizophrenia	18
BIPOLAR DISORDER	18
Signs and Symptoms	19
Causes and Risk Factors	19
Types	19

TOPIC	PAGE NO.
EATING DISORDERS	20
Signs and Symptoms	20
Causes and Risk Factors	21
Types	21
COGNITIVE DISORDERS	21
Signs and Symptoms	22
Causes and Risk Factors	22
Forms	22
PERSONALITY DISORDERS	23
Signs and Symptoms	23
Causes and Risk Factors	24
Types of Personality Disorders	24
SLEEP DISORDERS	24
Signs and Symptoms	25
Causes and Risk Factors	25
Forms	25
Insomnia	25
Sleep Apnea	26
Narcolepsy	26
CHILDHOOD AND ADOLESCENT MENTAL DISORDERS	26
Attention-Deficit/Hyperactivity Disorder (ADHD)	26
Signs and Symptoms	26
Causes and Risk Factors	27
Forms of ADHD	27
Autism	27
Signs and Symptoms	27
Communication	28
Social Skills	28
Unusual Behaviors and Interests	28
Causes	28
Forms of Autism Spectrum Disorders	29
Autistic Disorder	29
Asperger's Syndrome	29
Pervasive Developmental Disorder (PDD)	29
Rett Syndrome	29
Childhood Disintegrative Disorder	29
SUBSTANCE AND ALCOHOL ABUSE AS MENTAL DISORDERS	29
Signs and Symptoms of Substance Abuse	30
Causes and Risk Factors	30
Biology	30
Environment	30
Forms	30
Tobacco Addiction	31
Alcohol	31
Cocaine	31
Heroin	31

TOPIC	PAGE NO.
CHAPTER 4 REGULATORY ASPECTS	33
NEW DRUG APPROVALS	33
<i>TABLE 1 NEW DRUG APPROVALS FOR THE TREATMENT OF VARIOUS MENTAL DISORDERS, 2009 TO JULY 2013</i>	33
NEW DRUG APPLICATIONS	37
<i>TABLE 2 NEW DRUG APPLICATIONS, 2009 TO SEPTEMBER 2013</i>	37
RECALLS AND SAFETY ALERTS	38
<i>TABLE 3 RECALLS AND SAFETY ALERTS, 2009 TO SEPTEMBER 2013</i>	39
CHAPTER 5 PREVALENCE	41
OVERALL MENTAL ILLNESS	41
<i>TABLE 4 ANY MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS)</i>	42
<i>FIGURE 1 ANY MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS)</i>	42
<i>TABLE 5 SERIOUS MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS)</i>	43
<i>FIGURE 2 SERIOUS MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS)</i>	43
<i>TABLE 6 NUMBER OF CASES AFFECTED BY MENTAL DISORDERS IN EUROPE, 2011 (MILLIONS/%)</i>	44
<i>FIGURE 3 NUMBER OF CASES AFFECTED BY MENTAL DISORDERS IN EUROPE, 2011 (MILLIONS/%)</i>	44
DEPRESSION	44
ANXIETY DISORDERS	45
SCHIZOPHRENIA	45
EATING DISORDERS	45
COGNITIVE DISORDERS	46
SLEEP DISORDER	46
<i>TABLE 7 NUMBER OF CASES AFFECTED BY OBSTRUCTIVE SLEEP APNEA (OSA) IN VARIOUS COUNTRIES (%/MILLIONS)</i>	46
<i>FIGURE 4 NUMBER OF CASES AFFECTED BY OBSTRUCTIVE SLEEP APNEA (OSA) IN VARIOUS COUNTRIES (%/MILLIONS)</i>	47
PERSONALITY DISORDER	47
ALCOHOL AND SUBSTANCE ABUSE	47
CHILDHOOD AND ADOLESCENT MENTAL DISORDERS	48
CHAPTER 6 NEW DEVELOPMENTS	50
DEPRESSION	50
<i>TABLE 8 NEW DEVELOPMENTS IN DEPRESSION</i>	51
ANXIETY	53
<i>TABLE 9 NEW DEVELOPMENTS IN ANXIETY</i>	53
SCHIZOPHRENIA	54
<i>TABLE 10 NEW DEVELOPMENTS IN SCHIZOPHRENIA</i>	54
CHILDHOOD AND ADOLESCENT MENTAL DISORDERS	55
<i>TABLE 11 NEW DEVELOPMENTS IN CHILDHOOD AND ADOLESCENT MENTAL DISORDERS</i>	56
COGNITIVE DISORDERS	57
<i>TABLE 12 NEW DEVELOPMENTS IN COGNITIVE DISORDERS</i>	57

TOPIC	PAGE NO.
PERSONALITY DISORDERS	58
<i>TABLE 13 NEW DEVELOPMENTS IN PERSONALITY DISORDERS</i>	58
EATING DISORDERS	58
<i>TABLE 14 NEW DEVELOPMENTS IN EATING DISORDERS</i>	59
SUBSTANCE ABUSE	59
<i>TABLE 15 NEW DEVELOPMENTS IN SUBSTANCE ABUSE</i>	60
SLEEP DISORDER	60
<i>TABLE 16 NEW DEVELOPMENTS IN SLEEP DISORDERS</i>	60
CHAPTER 7 MARKET ANALYSIS	63
DEPRESSION AND ANTIDEPRESSANTS DRUG MARKET	63
MARKET BY REGION	64
Market Overview	64
Market Revenue	65
<i>TABLE 17 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	65
<i>FIGURE 5 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY REGION, 2011-2018 (\$ MILLIONS)</i>	65
Market Share	66
<i>TABLE 18 MARKET SHARE OF ANTIDEPRESSANTS BY REGION, 2012 (%)</i>	66
<i>FIGURE 6 MARKET SHARE OF ANTIDEPRESSANTS BY REGION, 2012 (%)</i>	66
MARKET BY TYPE	66
Market Overview	67
Market Revenue	68
<i>TABLE 19 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	68
<i>FIGURE 7 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY TYPE, 2011-2018 (\$ MILLIONS)</i>	68
ANTIPSYCHOTICS MARKET	69
MARKET BY REGION	69
Market Overview	69
Market Revenue	70
<i>TABLE 20 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	71
<i>FIGURE 8 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY REGION, 2011-2018 (\$ MILLIONS)</i>	71
Market Share	71
<i>TABLE 21 MARKET SHARE OF ANTIPSYCHOTICS BY REGION, 2012 (%)</i>	72
<i>FIGURE 9 MARKET SHARE OF ANTIPSYCHOTICS BY REGION, 2012 (%)</i>	72
MARKET BY TYPE	72
Market Overview	73
Market Revenue	74
<i>TABLE 22 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	74
<i>FIGURE 10 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY TYPE, 2011-2018 (\$ MILLIONS)</i>	74
ANXIETY DISORDERS AND ANXIOLYTICS MARKET	75
MARKET BY REGION	75
Market Overview	75

TOPIC	PAGE NO.
Market Revenue	75
<i>TABLE 23 MARKET REVENUE OF ANXIOLYTIC DRUGS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	76
<i>FIGURE 11 MARKET REVENUE OF ANXIOLYTIC DRUGS BY REGION, 2011-2018 (\$ MILLIONS)</i>	76
Market Share	76
<i>TABLE 24 MARKET SHARE OF ANXIOLYTICS BY REGION, 2012 (%)</i>	77
<i>FIGURE 12 MARKET SHARE OF ANXIOLYTICS BY REGION, 2012 (%)</i>	77
MARKET BY TYPE	77
Market Overview	77
Market Revenue	78
<i>TABLE 25 MARKET REVENUE OF ANTIANXIETY DRUGS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	78
<i>FIGURE 13 MARKET REVENUE OF ANTIANXIETY DRUGS BY TYPE, 2011-2018 (\$ MILLIONS)</i>	79
SCHIZOPHRENIA MEDICATION MARKET	79
MARKET BY REGION	79
Market Overview	79
Market Revenue	80
<i>TABLE 26 MARKET REVENUE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	81
<i>FIGURE 14 MARKET REVENUE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, 2011-2018 (\$ MILLIONS)</i>	81
Market Share	82
<i>TABLE 27 MARKET SHARE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, 2012 (%)</i>	82
<i>FIGURE 15 MARKET SHARE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, 2012 (%)</i>	82
MARKET BY TYPE	82
Market Overview	83
Market Revenue	84
<i>TABLE 28 MARKET REVENUE OF SCHIZOPHRENIC DRUGS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	84
<i>FIGURE 16 MARKET REVENUE OF SCHIZOPHRENIC DRUGS BY TYPE, 2011-2018 (\$ MILLIONS)</i>	85
BIPOLAR DISORDERS MARKET	85
MARKET BY REGION	85
Market Overview	86
Market Revenue	86
<i>TABLE 29 MARKET REVENUE FOR BIPOLAR DISORDER DRUGS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	87
<i>FIGURE 17 MARKET REVENUE FOR BIPOLAR DISORDER DRUGS BY REGION, 2011-2018 (\$ MILLIONS)</i>	87
Market Share	88
<i>TABLE 30 MARKET SHARE OF BIPOLAR DISORDER DRUGS BY REGION, 2012 (%)</i>	88
<i>FIGURE 18 MARKET SHARE OF BIPOLAR DISORDER DRUGS BY REGION, 2012 (%)</i>	88
MARKET BY TYPE	88
Market Overview	89
Market Revenue	89

TOPIC	PAGE NO.
<i>TABLE 31 MARKET REVENUE OF BIPOLAR DISORDER DRUGS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	90
<i>FIGURE 19 MARKET REVENUE OF BIPOLAR DISORDER DRUGS BY TYPE, 2011-2018 (\$ MILLIONS)</i>	90
CHILDHOOD AND ADOLESCENT MENTAL DISORDERS MARKET	90
MARKET BY REGION	91
Market Overview	91
Market Revenue	92
<i>TABLE 32 MARKET REVENUE FOR CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUGS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	93
<i>FIGURE 20 MARKET REVENUE FOR CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUGS BY REGION, 2011-2018 (\$ MILLIONS)</i>	94
Market Share	94
<i>TABLE 33 MARKET SHARE OF CHILDHOOD AND ADOLESCENT DISORDERS DRUGS BY REGION, 2012 (%)</i>	94
<i>FIGURE 21 MARKET SHARE OF CHILDHOOD AND ADOLESCENT DISORDERS DRUGS BY REGION, 2012 (%)</i>	94
MARKET BY TYPE	95
Market Overview	95
Market Revenue	96
<i>TABLE 34 MARKET REVENUE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUGS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	97
<i>FIGURE 22 MARKET REVENUE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUGS BY TYPE, 2011-2018 (\$ MILLIONS)</i>	97
EATING DISORDER DRUGS MARKET	97
COGNITIVE DISORDERS DRUGS MARKET	98
MARKET BY REGION	99
Market Overview	99
Market Revenue	100
<i>TABLE 35 MARKET REVENUE FOR COGNITIVE DISORDERS DRUGS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	100
<i>FIGURE 23 MARKET REVENUE FOR COGNITIVE DISORDERS DRUGS BY REGION, 2011-2018 (\$ MILLIONS)</i>	100
Market Share	101
<i>TABLE 36 MARKET SHARE OF COGNITIVE DISORDERS DRUGS BY REGION, 2012 (%)</i>	101
<i>FIGURE 24 MARKET SHARE OF COGNITIVE DISORDERS DRUGS BY REGION, 2012 (%)</i>	101
MARKET BY TYPE	102
Market Overview	103
Market Revenue	103
<i>TABLE 37 MARKET REVENUE OF COGNITIVE DISORDERS DRUGS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	104
<i>FIGURE 25 MARKET REVENUE OF COGNITIVE DISORDERS DRUGS BY TYPE, 2011-2018 (\$ MILLIONS)</i>	104
SUBSTANCE AND ALCOHOL ADDICTIONS AS MENTAL HEALTH DISORDERS	104
MARKET BY REGION	105
Market Overview	105
Market Revenue	106
<i>TABLE 38 MARKET REVENUE OF SUBSTANCE AND ALCOHOL ADDICTION DRUG PRODUCTS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	106

TOPIC	PAGE NO.
<i>FIGURE 26 MARKET REVENUE OF SUBSTANCE AND ALCOHOL ADDICTION DRUG PRODUCTS BY REGION, 2011-2018 (\$ MILLIONS)</i>	106
Market Share	107
<i>TABLE 39 MARKET SHARE OF SUBSTANCE ABUSE DRUGS BY REGION, 2012 (%)</i>	107
<i>FIGURE 27 MARKET SHARE OF SUBSTANCE ABUSE DRUGS BY REGION, 2012 (%)</i>	107
MARKET BY TYPE	108
Market Overview	108
Market Revenue	109
<i>TABLE 40 MARKET REVENUE OF DRUGS USED IN SUBSTANCE AND ALCOHOL ADDICTIONS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	110
<i>FIGURE 28 MARKET REVENUE OF DRUGS USED IN SUBSTANCE AND ALCOHOL ADDICTIONS BY TYPE, 2011-2018 (\$ MILLIONS)</i>	110
SLEEP DISORDERS AS MENTAL HEALTH CONDITIONS	111
MARKET BY REGION	111
Market Overview	111
Market Revenue	112
<i>TABLE 41 MARKET REVENUE FOR SLEEP DISORDER DRUGS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	112
<i>FIGURE 29 MARKET REVENUE FOR SLEEP DISORDER DRUGS BY REGION, 2011-2018 (\$ MILLIONS)</i>	112
Market Share	113
<i>TABLE 42 MARKET SHARE OF SLEEP DISORDERS THERAPEUTICS BY REGION, 2012 (%)</i>	113
<i>FIGURE 30 MARKET SHARE OF SLEEP DISORDERS THERAPEUTICS BY REGION, 2012 (%)</i>	113
MARKET BY TYPE	113
Market Overview	114
Market Revenue	114
<i>TABLE 43 MARKET REVENUE OF DRUGS USED IN SLEEP DISORDERS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	115
<i>FIGURE 31 MARKET REVENUE OF DRUGS USED IN SLEEP DISORDERS BY TYPE, 2011-2018 (\$ MILLIONS)</i>	115
PERSONALITY DISORDERS MARKET	116
DRUGS USED FOR OTHER MENTAL DISORDERS	116
CHAPTER 8 INDUSTRY STRUCTURE	120
ANTIDEPRESSANTS	120
MARKET LEADERS	120
<i>TABLE 44 GLOBAL MANUFACTURERS OF ANTIDEPRESSANTS, 2012</i>	120
MARKET SHARE	124
<i>TABLE 45 MARKET SHARE OF ANTIDEPRESSANT DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	125
<i>FIGURE 32 MARKET SHARE OF ANTIDEPRESSANT DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	125
ANTIPSYCHOTICS	125
MARKET LEADERS	125
<i>TABLE 46 GLOBAL MANUFACTURERS OF ANTIPSYCHOTICS, 2012</i>	126
MARKET SHARE	127
<i>TABLE 47 MARKET SHARE OF ANTIPSYCHOTIC DRUGS MANUFACTURING COMPANIES, 2012 (%)</i>	127

TOPIC	PAGE NO.
<i>FIGURE 33 MARKET SHARE OF ANTIPSYCHOTIC DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	128
ANTIANXIETY DRUGS	128
MARKET LEADERS	128
<i>TABLE 48 GLOBAL MANUFACTURERS OF DRUGS TO TREAT ANXIETY, 2012</i>	128
MARKET SHARE	131
<i>TABLE 49 MARKET SHARE OF ANTIANXIETY DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	131
<i>FIGURE 34 MARKET SHARE OF ANTIANXIETY DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	131
CHILDHOOD AND ADOLESCENT MENTAL DISORDERS	132
MARKET LEADERS	132
<i>TABLE 50 GLOBAL MANUFACTURERS OF DRUGS TO TREAT CHILDHOOD AND ADOLESCENT MENTAL DISORDERS, 2012</i>	132
MARKET SHARE	133
<i>TABLE 51 MARKET SHARE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	133
<i>FIGURE 35 MARKET SHARE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	134
BIPOLAR DISORDERS	134
MARKET LEADERS	134
<i>TABLE 52 GLOBAL MANUFACTURERS OF DRUGS TO TREAT BIPOLAR DISORDER, 2012</i>	134
MARKET SHARE	137
<i>TABLE 53 MARKET SHARE OF BIPOLAR DISORDER DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	138
<i>FIGURE 36 MARKET SHARE OF BIPOLAR DISORDER DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	138
COGNITIVE DISORDERS	139
MARKET LEADERS	139
<i>TABLE 54 GLOBAL MANUFACTURERS OF DRUGS TO TREAT COGNITIVE DISORDERS, 2012</i>	139
MARKET SHARE	140
<i>TABLE 55 MARKET SHARE OF COGNITIVE DISORDER DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	140
<i>FIGURE 37 MARKET SHARE OF COGNITIVE DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	140
SLEEP DISORDERS	141
MARKET LEADERS	141
<i>TABLE 56 GLOBAL MANUFACTURERS OF DRUGS TO TREAT SLEEP DISORDERS, 2012</i>	141
MARKET SHARE	142
<i>TABLE 57 MARKET SHARE OF SLEEP DISORDER DRUGS MANUFACTURING COMPANIES, 2012 (%)</i>	143
<i>FIGURE 38 MARKET SHARE OF SLEEP DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	143
SUBSTANCE ABUSE DRUGS	144
MARKET LEADERS	144
<i>TABLE 58 GLOBAL MANUFACTURERS OF DRUGS TO TREAT SUBSTANCE ABUSE, 2012</i>	144

TOPIC	PAGE NO.
MARKET SHARE	145
<i>TABLE 59 MARKET SHARE OF SUBSTANCE ABUSE DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	146
<i>FIGURE 39 MARKET SHARE OF SUBSTANCE ABUSE DRUG MANUFACTURING COMPANIES, 2012 (%)</i>	146
CHAPTER 9 PATENT ANALYSIS	148
PATENTS BY YEAR	148
<i>TABLE 60 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2009 TO SEPTEMBER 2013</i>	148
<i>FIGURE 40 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2009 TO SEPTEMBER 2013</i>	148
PATENTS BY TYPE/CATEGORY	149
<i>TABLE 61 PATENTS BY CATEGORY, JANUARY 2009 TO SEPTEMBER 2013</i>	149
<i>FIGURE 41 PATENTS BY CATEGORY, JANUARY 2009 TO SEPTEMBER 2013</i>	150
PATENTS BY COMPANY	150
<i>TABLE 62 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009 TO JUNE 2013</i>	151
PATENTS BY COUNTRY	153
<i>TABLE 63 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009 TO SEPTEMBER 2013</i>	153
<i>TABLE 64 PATENT SHARES BY COUNTRY, JANUARY 2009 TO SEPTEMBER 2013 (%)</i>	154
<i>FIGURE 42 PATENT SHARES BY COUNTRY, JANUARY 2009 TO SEPTEMBER 2013 (%)</i>	155
PATENTS BY ASSIGNEE	155
<i>TABLE 65 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009 TO JUNE 2013</i>	155
<i>FIGURE 43 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009 TO JUNE 2013</i>	155
CHAPTER 10 COMPANY PROFILES	158
ABBVIE INC	158
ACTAVIS PLC	158
ALEMBIC PHARMACEUTICALS LTD.	159
ALKERMES PLC	159
AMEDRA PHARMCEUTICALS	160
ANGELINI PHARMA	160
APOTEX PHARMACHEM	161
ASTRAZENECA	161
BOEHRINGER INGELHEIM	162
BRISTOL-MYERS SQUIBB	162
CIPLA	163
COVIS PHARMA	163
CYPRESS BIOSCIENCE	164
DR. REDDY'S LABORATORIES	164
EDGEMONT PHARMS LLC	165
EISAI INC	165
ELI LILLY & COMPANY	166
FOREST LABS	167
FOUGERA PHARMACEUTICALS INC.	167
FRESENIUS KABI USA	167
GLAXOSMITHKLINE	168

TOPIC	PAGE NO.
GLENMARK PHARMACEUTICALS	168
HOFFMAN-LA-ROCHE	169
HOSPIRA	169
JANSSEN-CILAG	170
JOHNSON & JOHNSON	170
JAZZ PHARMACEUTICALS	171
LUNDBECK LLC	172
LUPIN PHARMACEUTICALS INC.	172
MALLINCKRODT PHARMACEUTICALS	172
MERCK AND CO.	173
MYLAN INC.	174
NOVARTIS	174
NOVEL LABS INC.	175
NOVEN PHARMACEUTICALS INC.	175
OREXO AB	176
OSMOTICA PHARMACEUTICAL CORP.	176
OTSUKA AMERICA PHARMACEUTICAL INC.	177
PAR PHARMACEUTICAL COMPANIES INC.	177
PERNIX THERAPEUTICS	178
PFIZER INC.	178
PURDUE PHARMA LP	179
RANBAXY	180
RECKITT BENCKISER	180
ROXANE LABORATORIES LTD.	181
SANDOZ INTERNATIONAL GMBH	181
SANOFI	182
SHIRE	183
SUN PHARMA GLOBAL	183
SUNOVION PHARMS INC	184
TAKEDA PHARMACEUTICALS	184
TARO PHARMACEUTICAL INDUSTRIES	185
TEVA PHARMACEUTICAL INDUSTRIES LTD.	185
TORRENT PHARMACEUTICALS LIMITED	186
UCB COMPANY	186
UNICHEM LABORATORIES LIMITED	187
VALEANT PHARMACEUTICAL INTERNATIONAL INC	187
VALIDUS PHARMACEUTICALS LLC	187
WATSON LABS	188
WOCKHARDT LIMITED	188
ZYDUS PHARMACEUTICALS INC	189
CHAPTER 11 APPENDIX-ABBREVIATIONS	191

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL REVENUE OF DRUGS USED IN MENTAL DISORDERS, THROUGH 2018 (\$ MILLIONS)	8
TABLE 1 NEW DRUG APPROVALS FOR THE TREATMENT OF VARIOUS MENTAL DISORDERS, 2009 TO JULY 2013	33
TABLE 2 NEW DRUG APPLICATIONS, 2009 TO SEPTEMBER 2013	37
TABLE 3 RECALLS AND SAFETY ALERTS, 2009 TO SEPTEMBER 2013	39
TABLE 4 ANY MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS)	42
TABLE 5 SERIOUS MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS)	43
TABLE 6 NUMBER OF CASES AFFECTED BY MENTAL DISORDERS IN EUROPE, 2011 (MILLIONS/%)	44
TABLE 7 NUMBER OF CASES AFFECTED BY OBSTRUCTIVE SLEEP APNEA (OSA) IN VARIOUS COUNTRIES (%/MILLIONS)	46
TABLE 8 NEW DEVELOPMENTS IN DEPRESSION	51
TABLE 9 NEW DEVELOPMENTS IN ANXIETY	53
TABLE 10 NEW DEVELOPMENTS IN SCHIZOPHRENIA	54
TABLE 11 NEW DEVELOPMENTS IN CHILDHOOD AND ADOLESCENT MENTAL DISORDERS	56
TABLE 12 NEW DEVELOPMENTS IN COGNITIVE DISORDERS	57
TABLE 13 NEW DEVELOPMENTS IN PERSONALITY DISORDERS	58
TABLE 14 NEW DEVELOPMENTS IN EATING DISORDERS	59
TABLE 15 NEW DEVELOPMENTS IN SUBSTANCE ABUSE	60
TABLE 16 NEW DEVELOPMENTS IN SLEEP DISORDERS	60
TABLE 17 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY REGION, THROUGH 2018 (\$ MILLIONS)	65
TABLE 18 MARKET SHARE OF ANTIDEPRESSANTS BY REGION, 2012 (%)	66
TABLE 19 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY TYPE, THROUGH 2018 (\$ MILLIONS)	68
TABLE 20 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY REGION, THROUGH 2018 (\$ MILLIONS)	71
TABLE 21 MARKET SHARE OF ANTIPSYCHOTICS BY REGION, 2012 (%)	72
TABLE 22 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY TYPE, THROUGH 2018 (\$ MILLIONS)	74
TABLE 23 MARKET REVENUE OF ANXIOLYTIC DRUGS BY REGION, THROUGH 2018 (\$ MILLIONS)	76
TABLE 24 MARKET SHARE OF ANXIOLYTICS BY REGION, 2012 (%)	77
TABLE 25 MARKET REVENUE OF ANTIANXIETY DRUGS BY TYPE, THROUGH 2018 (\$ MILLIONS)	78
TABLE 26 MARKET REVENUE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, THROUGH 2018 (\$ MILLIONS)	81
TABLE 27 MARKET SHARE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, 2012 (%)	82
TABLE 28 MARKET REVENUE OF SCHIZOPHRENIC DRUGS BY TYPE, THROUGH 2018 (\$ MILLIONS)	84
TABLE 29 MARKET REVENUE FOR BIPOLAR DISORDER DRUGS BY REGION, THROUGH 2018 (\$ MILLIONS)	87
TABLE 30 MARKET SHARE OF BIPOLAR DISORDER DRUGS BY REGION, 2012 (%)	88
TABLE 31 MARKET REVENUE OF BIPOLAR DISORDER DRUGS BY TYPE, THROUGH 2018 (\$ MILLIONS)	90

TABLE HEADING	PAGE NO.
TABLE 32 MARKET REVENUE FOR CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUGS BY REGION, THROUGH 2018 (\$ MILLIONS)	93
TABLE 33 MARKET SHARE OF CHILDHOOD AND ADOLESCENT DISORDERS DRUGS BY REGION, 2012 (%)	94
TABLE 34 MARKET REVENUE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUGS BY TYPE, THROUGH 2018 (\$ MILLIONS)	97
TABLE 35 MARKET REVENUE FOR COGNITIVE DISORDERS DRUGS BY REGION, THROUGH 2018 (\$ MILLIONS)	100
TABLE 36 MARKET SHARE OF COGNITIVE DISORDERS DRUGS BY REGION, 2012 (%)	101
TABLE 37 MARKET REVENUE OF COGNITIVE DISORDERS DRUGS BY TYPE, THROUGH 2018 (\$ MILLIONS)	104
TABLE 38 MARKET REVENUE OF SUBSTANCE AND ALCOHOL ADDICTION DRUG PRODUCTS BY REGION, THROUGH 2018 (\$ MILLIONS)	106
TABLE 39 MARKET SHARE OF SUBSTANCE ABUSE DRUGS BY REGION, 2012 (%)	107
TABLE 40 MARKET REVENUE OF DRUGS USED IN SUBSTANCE AND ALCOHOL ADDICTIONS BY TYPE, THROUGH 2018 (\$ MILLIONS)	110
TABLE 41 MARKET REVENUE FOR SLEEP DISORDER DRUGS BY REGION, THROUGH 2018 (\$ MILLIONS)	112
TABLE 42 MARKET SHARE OF SLEEP DISORDERS THERAPEUTICS BY REGION, 2012 (%)	113
TABLE 43 MARKET REVENUE OF DRUGS USED IN SLEEP DISORDERS BY TYPE, THROUGH 2018 (\$ MILLIONS)	115
TABLE 44 GLOBAL MANUFACTURERS OF ANTIDEPRESSANTS, 2012	120
TABLE 45 MARKET SHARE OF ANTIDEPRESSANT DRUG MANUFACTURING COMPANIES, 2012 (%)	125
TABLE 46 GLOBAL MANUFACTURERS OF ANTIPSYCHOTICS, 2012	126
TABLE 47 MARKET SHARE OF ANTIPSYCHOTIC DRUGS MANUFACTURING COMPANIES, 2012 (%)	127
TABLE 48 GLOBAL MANUFACTURERS OF DRUGS TO TREAT ANXIETY, 2012	128
TABLE 49 MARKET SHARE OF ANTIANXIETY DRUG MANUFACTURING COMPANIES, 2012 (%)	131
TABLE 50 GLOBAL MANUFACTURERS OF DRUGS TO TREAT CHILDHOOD AND ADOLESCENT MENTAL DISORDERS, 2012	132
TABLE 51 MARKET SHARE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%)	133
TABLE 52 GLOBAL MANUFACTURERS OF DRUGS TO TREAT BIPOLAR DISORDER, 2012	134
TABLE 53 MARKET SHARE OF BIPOLAR DISORDER DRUG MANUFACTURING COMPANIES, 2012 (%)	138
TABLE 54 GLOBAL MANUFACTURERS OF DRUGS TO TREAT COGNITIVE DISORDERS, 2012	139
TABLE 55 MARKET SHARE OF COGNITIVE DISORDER DRUG MANUFACTURING COMPANIES, 2012 (%)	140
TABLE 56 GLOBAL MANUFACTURERS OF DRUGS TO TREAT SLEEP DISORDERS, 2012	141
TABLE 57 MARKET SHARE OF SLEEP DISORDER DRUGS MANUFACTURING COMPANIES, 2012 (%)	143
TABLE 58 GLOBAL MANUFACTURERS OF DRUGS TO TREAT SUBSTANCE ABUSE, 2012	144
TABLE 59 MARKET SHARE OF SUBSTANCE ABUSE DRUG MANUFACTURING COMPANIES, 2012 (%)	146
TABLE 60 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2009 TO SEPTEMBER 2013	148

TABLE HEADING	PAGE NO.
TABLE 61 PATENTS BY CATEGORY, JANUARY 2009 TO SEPTEMBER 2013	149
TABLE 62 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009 TO JUNE 2013	151
TABLE 63 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009 TO SEPTEMBER 2013	153
TABLE 64 PATENT SHARES BY COUNTRY, JANUARY 2009 TO SEPTEMBER 2013 (%)	154
TABLE 65 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009 TO JUNE 2013	155

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL REVENUE OF DRUGS USED IN MENTAL DISORDERS, 2011-2018 (\$ MILLIONS)	8
FIGURE 1 ANY MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS)	42
FIGURE 2 SERIOUS MENTAL ILLNESS AMONG U.S. PEOPLE AGE 18 YEARS OR OLDER, 2010 AND 2011 (THOUSANDS)	43
FIGURE 3 NUMBER OF CASES AFFECTED BY MENTAL DISORDERS IN EUROPE, 2011 (MILLIONS/%)	44
FIGURE 4 NUMBER OF CASES AFFECTED BY OBSTRUCTIVE SLEEP APNEA (OSA) IN VARIOUS COUNTRIES (%/MILLIONS)	47
FIGURE 5 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY REGION, 2011-2018 (\$ MILLIONS)	65
FIGURE 6 MARKET SHARE OF ANTIDEPRESSANTS BY REGION, 2012 (%)	66
FIGURE 7 GLOBAL MARKET REVENUE OF ANTIDEPRESSANTS BY TYPE, 2011-2018 (\$ MILLIONS)	68
FIGURE 8 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY REGION, 2011-2018 (\$ MILLIONS)	71
FIGURE 9 MARKET SHARE OF ANTIPSYCHOTICS BY REGION, 2012 (%)	72
FIGURE 10 GLOBAL MARKET REVENUE OF ANTIPSYCHOTICS BY TYPE, 2011-2018 (\$ MILLIONS)	74
FIGURE 11 MARKET REVENUE OF ANXIOLYTIC DRUGS BY REGION, 2011-2018 (\$ MILLIONS)	76
FIGURE 12 MARKET SHARE OF ANXIOLYTICS BY REGION, 2012 (%)	77
FIGURE 13 MARKET REVENUE OF ANTIANXIETY DRUGS BY TYPE, 2011-2018 (\$ MILLIONS)	79
FIGURE 14 MARKET REVENUE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, 2011-2018 (\$ MILLIONS)	81
FIGURE 15 MARKET SHARE OF DRUGS USED IN SCHIZOPHRENIA BY REGION, 2012 (%)	82
FIGURE 16 MARKET REVENUE OF SCHIZOPHRENIC DRUGS BY TYPE, 2011-2018 (\$ MILLIONS)	85
FIGURE 17 MARKET REVENUE FOR BIPOLAR DISORDER DRUGS BY REGION, 2011-2018 (\$ MILLIONS)	87
FIGURE 18 MARKET SHARE OF BIPOLAR DISORDER DRUGS BY REGION, 2012 (%)	88
FIGURE 19 MARKET REVENUE OF BIPOLAR DISORDER DRUGS BY TYPE, 2011-2018 (\$ MILLIONS)	90
FIGURE 20 MARKET REVENUE FOR CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUGS BY REGION, 2011-2018 (\$ MILLIONS)	94
FIGURE 21 MARKET SHARE OF CHILDHOOD AND ADOLESCENT DISORDERS DRUGS BY REGION, 2012 (%)	94
FIGURE 22 MARKET REVENUE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUGS BY TYPE, 2011-2018 (\$ MILLIONS)	97
FIGURE 23 MARKET REVENUE FOR COGNITIVE DISORDERS DRUGS BY REGION, 2011-2018 (\$ MILLIONS)	100
FIGURE 24 MARKET SHARE OF COGNITIVE DISORDERS DRUGS BY REGION, 2012 (%)	101
FIGURE 25 MARKET REVENUE OF COGNITIVE DISORDERS DRUGS BY TYPE, 2011-2018 (\$ MILLIONS)	104
FIGURE 26 MARKET REVENUE OF SUBSTANCE AND ALCOHOL ADDICTION DRUG PRODUCTS BY REGION, 2011-2018 (\$ MILLIONS)	106
FIGURE 27 MARKET SHARE OF SUBSTANCE ABUSE DRUGS BY REGION, 2012 (%)	107

FIGURE TITLE	PAGE NO.
FIGURE 28 MARKET REVENUE OF DRUGS USED IN SUBSTANCE AND ALCOHOL ADDICTIONS BY TYPE, 2011-2018 (\$ MILLIONS)	110
FIGURE 29 MARKET REVENUE FOR SLEEP DISORDER DRUGS BY REGION, 2011-2018 (\$ MILLIONS)	112
FIGURE 30 MARKET SHARE OF SLEEP DISORDERS THERAPEUTICS BY REGION, 2012 (%)	113
FIGURE 31 MARKET REVENUE OF DRUGS USED IN SLEEP DISORDERS BY TYPE, 2011-2018 (\$ MILLIONS)	115
FIGURE 32 MARKET SHARE OF ANTIDEPRESSANT DRUG MANUFACTURING COMPANIES, 2012 (%)	125
FIGURE 33 MARKET SHARE OF ANTIPSYCHOTIC DRUG MANUFACTURING COMPANIES, 2012 (%)	128
FIGURE 34 MARKET SHARE OF ANTIANXIETY DRUG MANUFACTURING COMPANIES, 2012 (%)	131
FIGURE 35 MARKET SHARE OF CHILDHOOD AND ADOLESCENT MENTAL DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%)	134
FIGURE 36 MARKET SHARE OF BIPOLAR DISORDER DRUG MANUFACTURING COMPANIES, 2012 (%)	138
FIGURE 37 MARKET SHARE OF COGNITIVE DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%)	140
FIGURE 38 MARKET SHARE OF SLEEP DISORDERS DRUG MANUFACTURING COMPANIES, 2012 (%)	143
FIGURE 39 MARKET SHARE OF SUBSTANCE ABUSE DRUG MANUFACTURING COMPANIES, 2012 (%)	146
FIGURE 40 NUMBER OF SIGNIFICANT PATENTS BY YEAR, JANUARY 2009 TO SEPTEMBER 2013	148
FIGURE 41 PATENTS BY CATEGORY, JANUARY 2009 TO SEPTEMBER 2013	150
FIGURE 42 PATENT SHARES BY COUNTRY, JANUARY 2009 TO SEPTEMBER 2013 (%)	155
FIGURE 43 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009 TO JUNE 2013	155